Research programme: obesity therapy - Synergy Pharmaceuticals
Latest Information Update: 24 Apr 2007
At a glance
- Originator Synergy Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 07 May 2003 Synergy Pharmaceuticals has been acquired by Webtronics
- 11 Apr 2000 Preclinical development for Obesity in USA (Unknown route)